Switch Studies / Alternating Regimens

Switching from Lopinavir/Ritonavir to Unboosted Atazanavir Lowers Lipids - 9/01/06

Switching from Various Triple HAART Regimens to Lopinavir/Ritonavir Monotherapy in Selected Patients   - 8/18/06

Effects of Switching from Fixed Dose Zidovudine/Lamivudine (CBV) to Fixed Dose Tenofovir DF/Emtricitabine (TVD): Maintenance of Virologic Suppression and Other Benefits. E DeJesus and others. - 12/18/05

Switching from a Protease Inhibitor (PI) to Nevirapine Is as Effective as Continuing with PI for Viral Suppression and Improves Lipodystrophy - 9/23/05

Adherence Is Better after Switching from Twice-daily to Once-daily Therapy for HIV: Treatment Simplification Using Stavudine Prolonged-release Capsules - 5/25/05

High Virological Failure Rate in Patients Switching to a Regimen with Two Nucleoside Reverse Transcriptase Inhibitors Plus Tenofovir - 4/11/05

Switch from Ritonavir to Indinavir in Combination Therapy for Children with HIV - 4/06/05

Switch from Zidovudine or Stavudine to Abacavir or Tenofovir for 48 Weeks Significantly Improves Lipoatrophy and Dyslipidemia and Maintains Viral Suppression: The RAVE Study - 3/02/05

Simplification Therapy with Once Daily Emtricitabine, Didanosine, and Efavirenz in HIV Positive Adults with Viral Suppression Receiving a Protease Inhibitor-based Regimen - 2/18/05

Development of Hepatotoxicity in HIV Patients Switching at Least One Protease Inhibitor - 2/16/05

Substituting Abacavir for Hyperlipidemia-associated PIs Improves Lipid Profiles, Maintains Virologic Suppression, and Simplifies Treatment - 1/24/05

Alternation of Antiretroviral Drug Regimens for HIV Infection: Efficacy, Safety and Tolerability at Week 96 of the Swatch Study - 1/26/05

Long-Term Efficacy and Safety of Switch from Protease Inhibitor to NNRTI Nevirapine in Patients with Undetectable HIV Viral Load - 09/22/04

24 Weeks After Substitution of Nevirapine for Protease Inhibitors, Lipid Profile and Adiponectin Concentration Improve Significantly  - 08/23/04

Evaluation of Side Effects Related to HIV and Its Treatment in Patients Before and After Substitution of Their PI/NNRTI with Lopinavir/Ritonavir - 08/04/04

Efficacy and Safety of Switch to Fosamprenavir/Ritonavir 200mg QD in Subjects Initiating Therapy with Amprenavir/Ritonavir 200mg QD  - 07/19/04

Treatment of Pediatric HIV in the US from 1987 to 2003 - 07/14/04

Virological Phenotype Switches in Salvage Therapy with Lopinavir/Ritonavir in Heavily Pretreated, HIV Vertically-infected Children  - 07/14/04

Estimating the Optimal Threshold for Initiating Antiretroviral Therapy in HIV Disease - 07/12/04

Impact of Switching Antiretroviral Therapy on Lipodystrophy and Other Metabolic Complications: A Review - 06/23/04

Long-Term Efficacy and Safety of Atazanavir with Stavudine and Lamivudine in Patients Previously Treated with Nelfinavir or Atazanavir  - 06/04/04

No Relationship Between High Nevirapine Plasma Concentration and Hepatotoxicity in Treatment-naïve HIV Patients or in Those Switched from Protease Inhibitors  - 06/04/04